136 related articles for article (PubMed ID: 30881995)
1. Functional Variant rs4442975 Modulating FOXA1 Binding Affinity Can Influence Bone Marrow Suppression during Neoadjuvant Chemotherapy for Luminal A Type Breast Cancer.
Wang X; Feng Z; Li J; Han Y; Su L; Wang F; Yang Y; Zhang Y
Biomed Res Int; 2019; 2019():7073498. PubMed ID: 30881995
[TBL] [Abstract][Full Text] [Related]
2. A functional variant rs4442975 modulating FOXA1-binding affinity does not influence the risk or progression of breast cancer in Chinese Han population.
Zhang Y; Li Y; Jiang S; Chen W; Lou J; Ke J; Li J; Zhu Y; Gong Y; Yang Y; Tian J; Peng X; Zou D; Gong J; Chang J; Miao X; Zhong R
Oncotarget; 2016 Dec; 7(49):81691-81697. PubMed ID: 27835577
[TBL] [Abstract][Full Text] [Related]
3. FOXA1 Expression Significantly Predict Response to Chemotherapy in Estrogen Receptor-Positive Breast Cancer Patients.
Xu C; Wei Q; Guo J; Zhou JC; Mei J; Jiang ZN; Shen JG; Wang LB
Ann Surg Oncol; 2015; 22(6):2034-9. PubMed ID: 25707489
[TBL] [Abstract][Full Text] [Related]
4. FOXA1 expression after neoadjuvant chemotherapy is a prognostic marker in estrogen receptor-positive breast cancer.
Kawase M; Toyama T; Takahashi S; Sato S; Yoshimoto N; Endo Y; Asano T; Kobayashi S; Fujii Y; Yamashita H
Breast Cancer; 2015 May; 22(3):308-16. PubMed ID: 23771556
[TBL] [Abstract][Full Text] [Related]
5. Low FOXA1 expression predicts good response to neo-adjuvant chemotherapy resulting in good outcomes for luminal HER2-negative breast cancer cases.
Horimoto Y; Arakawa A; Harada-Shoji N; Sonoue H; Yoshida Y; Himuro T; Igari F; Tokuda E; Mamat O; Tanabe M; Hino O; Saito M
Br J Cancer; 2015 Jan; 112(2):345-51. PubMed ID: 25422910
[TBL] [Abstract][Full Text] [Related]
6. Analysis of the relevance between molecular subtypes and efficacy of neoadjuvant chemotherapy in breast cancer as well as its prognostic factors.
Li F; Ma L; Geng C; Liu C; Deng H; Yue M; Ding Y; Wang X; Liu Y
Pathol Res Pract; 2018 Aug; 214(8):1166-1172. PubMed ID: 29945816
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of pathologic complete response and Ki67 expression after neoadjuvant chemotherapy in breast cancer.
Yoshioka T; Hosoda M; Yamamoto M; Taguchi K; Hatanaka KC; Takakuwa E; Hatanaka Y; Matsuno Y; Yamashita H
Breast Cancer; 2015 Mar; 22(2):185-91. PubMed ID: 23645542
[TBL] [Abstract][Full Text] [Related]
8. Association of LncRNA MEG3 polymorphisms with efficacy of neoadjuvant chemotherapy in breast cancer.
Bayarmaa B; Wu Z; Peng J; Wang Y; Xu S; Yan T; Yin W; Lu J; Zhou L
BMC Cancer; 2019 Sep; 19(1):877. PubMed ID: 31488093
[TBL] [Abstract][Full Text] [Related]
9. Progesterone receptor loss identifies luminal-type local advanced breast cancer with poor survival in patients who fail to achieve a pathological complete response to neoadjuvant chemotherapy.
Chen S; Huang L; Chen CM; Shao ZM
Oncotarget; 2015 Jul; 6(20):18174-82. PubMed ID: 26053183
[TBL] [Abstract][Full Text] [Related]
10. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.
Denkert C; von Minckwitz G; Darb-Esfahani S; Lederer B; Heppner BI; Weber KE; Budczies J; Huober J; Klauschen F; Furlanetto J; Schmitt WD; Blohmer JU; Karn T; Pfitzner BM; Kümmel S; Engels K; Schneeweiss A; Hartmann A; Noske A; Fasching PA; Jackisch C; van Mackelenbergh M; Sinn P; Schem C; Hanusch C; Untch M; Loibl S
Lancet Oncol; 2018 Jan; 19(1):40-50. PubMed ID: 29233559
[TBL] [Abstract][Full Text] [Related]
11. The prognostic relevance of FOXA1 and Nestin expression in breast cancer metastases: a retrospective study of 164 cases during a 10-year period (2004-2014).
De Lara S; Nyqvist J; Werner Rönnerman E; Helou K; Kenne Sarenmalm E; Einbeigi Z; Karlsson P; Parris TZ; Kovács A
BMC Cancer; 2019 Feb; 19(1):187. PubMed ID: 30819139
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant everolimus plus letrozole versus fluorouracil, epirubicin and cyclophosphamide for ER-positive, HER2-negative breast cancer: study protocol for a randomized pilot trial.
Wu W; Deng H; Rao N; You N; Yang Y; Cao M; Liu J
Trials; 2017 Oct; 18(1):497. PubMed ID: 29070044
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and prognosis of neoadjuvant chemotherapy is correlated with breast cancer molecular classification.
Dai XL; Han ZB; Yang YT; Qiu J; Liu YF; Feng YZ
Int J Clin Pharmacol Ther; 2015 Jul; 53(7):517-22. PubMed ID: 25907177
[TBL] [Abstract][Full Text] [Related]
14. PAM50 for prediction of response to neoadjuvant chemotherapy for ER-positive breast cancer.
Ohara AM; Naoi Y; Shimazu K; Kagara N; Shimoda M; Tanei T; Miyake T; Kim SJ; Noguchi S
Breast Cancer Res Treat; 2019 Feb; 173(3):533-543. PubMed ID: 30361874
[TBL] [Abstract][Full Text] [Related]
15. Preoperative neoadjuvant chemotherapy using nanoparticle albumin-bound paclitaxel followed by epirubicin and cyclophosphamide for operable breast cancer: a multicenter phase II trial.
Futamura M; Nagao Y; Ishihara K; Takeuchi M; Nakada T; Kawaguchi Y; Asano M; Kumazawa I; Shiroko T; Morimitsu K; Mori R; Nawa M; Shimokawa T; Yoshida K
Breast Cancer; 2017 Jul; 24(4):615-623. PubMed ID: 28050738
[TBL] [Abstract][Full Text] [Related]
16. Bevacizumab plus neoadjuvant chemotherapy in patients with HER2-negative inflammatory breast cancer (BEVERLY-1): a multicentre, single-arm, phase 2 study.
Bertucci F; Fekih M; Autret A; Petit T; Dalenc F; Levy C; Romieu G; Bonneterre J; Ferrero JM; Kerbrat P; Soulie P; Mouret-Reynier MA; Bachelot T; Lerebours F; Eymard JC; Deblock M; Lortholary A; Hardy-Bessard AC; Barthelemy P; Bonnefoi H; Charafe-Jauffret E; Bidard FC; Viens P; Lemonnier J; Pierga JY
Lancet Oncol; 2016 May; 17(5):600-11. PubMed ID: 27032301
[TBL] [Abstract][Full Text] [Related]
17. Assessment of the predictive role of pretreatment Ki-67 and Ki-67 changes in breast cancer patients receiving neoadjuvant chemotherapy according to the molecular classification: a retrospective study of 1010 patients.
Chen R; Ye Y; Yang C; Peng Y; Zong B; Qu F; Tang Z; Wang Y; Su X; Li H; Yang G; Liu S
Breast Cancer Res Treat; 2018 Jul; 170(1):35-43. PubMed ID: 29480449
[TBL] [Abstract][Full Text] [Related]
18. Twist1 promotes breast cancer invasion and metastasis by silencing Foxa1 expression.
Xu Y; Qin L; Sun T; Wu H; He T; Yang Z; Mo Q; Liao L; Xu J
Oncogene; 2017 Feb; 36(8):1157-1166. PubMed ID: 27524420
[TBL] [Abstract][Full Text] [Related]
19. Outcome after neoadjuvant chemotherapy in estrogen receptor-positive and progesterone receptor-negative breast cancer patients: a pooled analysis of individual patient data from ten prospectively randomized controlled neoadjuvant trials.
van Mackelenbergh MT; Denkert C; Nekljudova V; Karn T; Schem C; Marmé F; Stickeler E; Jackisch C; Hanusch C; Huober J; Fasching PA; Blohmer JU; Kümmel S; Müller V; Schneeweiss A; Untch M; von Minckwitz G; Weber KE; Loibl S
Breast Cancer Res Treat; 2018 Jan; 167(1):59-71. PubMed ID: 28875243
[TBL] [Abstract][Full Text] [Related]
20. Docetaxel followed by fluorouracil/epirubicin/cyclophosphamide as neoadjuvant chemotherapy for patients with primary breast cancer.
Iwata H; Sato N; Masuda N; Nakamura S; Yamamoto N; Kuroi K; Kurosumi M; Tsuda H; Akiyama F; Ohashi Y; Toi M
Jpn J Clin Oncol; 2011 Jul; 41(7):867-75. PubMed ID: 21719750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]